Fmr LLC

recently revealed that they own 8.7% of Aclaris Therapeutics Inc (NASDAQ:ACRS) in a Form 13G/A disclosure that was filed with the Securities and Exchange Commission (SEC) on Tuesday, February 13th. The investor owns 2,673,260 shares of the stock worth $52,075,105. The disclosure is available through the SEC website at this hyperlink.

A number of other institutional investors and hedge funds have also modified their holdings of ACRS. Citigroup Inc. lifted its position in shares of Aclaris Therapeutics by 171.8% in the second quarter. Citigroup Inc. now owns 4,313 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 2,726 shares in the last quarter. Legal & General Group Plc lifted its position in shares of Aclaris Therapeutics by 98.3% in the second quarter. Legal & General Group Plc now owns 5,254 shares of the biotechnology company’s stock valued at $142,000 after acquiring an additional 2,605 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Aclaris Therapeutics in the third quarter valued at approximately $142,000. Teacher Retirement System of Texas purchased a new position in shares of Aclaris Therapeutics in the fourth quarter valued at approximately $200,000. Finally, Voya Investment Management LLC purchased a new position in shares of Aclaris Therapeutics in the second quarter valued at approximately $247,000. 92.47% of the stock is currently owned by institutional investors.

ACRS has been the topic of several research reports. Cantor Fitzgerald restated a “buy” rating and issued a $50.00 target price on shares of Aclaris Therapeutics in a research report on Tuesday, November 7th. Guggenheim initiated coverage on Aclaris Therapeutics in a research report on Thursday, February 8th. They issued a “buy” rating and a $53.00 target price on the stock. Zacks Investment Research downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Finally, BidaskClub downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, December 20th. Three analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Aclaris Therapeutics currently has a consensus rating of “Hold” and an average price target of $41.80.

Shares of Aclaris Therapeutics Inc (NASDAQ:ACRS) traded up $0.38 during trading on Tuesday, reaching $19.48. The company had a trading volume of 196,220 shares, compared to its average volume of 374,037. Aclaris Therapeutics Inc has a 52-week low of $18.46 and a 52-week high of $33.25. The stock has a market capitalization of $586.17, a P/E ratio of -8.84 and a beta of 1.26.

TRADEMARK VIOLATION NOTICE: “Fmr LLC Has Stake in Aclaris Therapeutics Inc (ACRS)” was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://theolympiareport.com/2018/02/13/fmr-llc-has-stake-in-aclaris-therapeutics-inc-acrs.html.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Want to see what other hedge funds are holding ACRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aclaris Therapeutics Inc (NASDAQ:ACRS).

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.